Why the study?
Current deferral guidelines are not established for NSAID use before PRP injections, despite NSAIDs inhibiting platelet degranulation.
Do COX-1 inhibiting NSAIDs affect platelet aggregation and TxB2 titers in healthy human volunteers?
Systematic Review (n=522)
Do COX-1 inhibiting NSAIDs affect platelet aggregation and TxB2 titers in healthy human volunteers?
Answers are grounded in this paper and cite their sources.
Different NSAIDs require varying deferral times before platelet-rich plasma (PRP) injections based on their duration of COX-1 mediated platelet inhibition, with naproxen requiring 24-48 hours and acetaminophen requiring no deferral.
Platelet-rich plasma (PRP) is an autologous blood product containing concentrated platelets, growth factors, and anti-inflammatory cytokines that promote healing and regeneration. Platelets release active components through a degranulation process, which is inhibited by certain nonsteroidal anti-inflammatory drugs (NSAIDs). Current deferral guidelines are not established, but NSAIDs are expected to have a time-dose relationship with platelet inhibition. This article aims to review the literature regarding NSAIDs that inhibit a key enzyme in clotting, cyclooxygenase-1 (COX-1), and their effects on bulk platelet aggregation to establish guidelines for deferral times before PRP injections. After searching the literature, 25 studies met the inclusion criteria for this review. Our analysis of the data revealed several significant findings. Naproxen demonstrated inhibition of platelet aggregation lasting at least 24 hours, with possible inhibition even at 48 hours. Studies using indomethacin found recovery by 24 hours, although no other time points were measured. Ibuprofen and diclofenac inhibit platelet aggregation for 6-12 hours, depending on dose. Acetaminophen, a mild inhibitor of COX-1, does not require deferral. These results reinforce the need to defer NSAIDs with COX-1 activity before PRP injections. This review will allow for the creation of deferral guidelines that differentiate NSAIDs based on their length of platelet inhibition.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) conducted a systematic review in Healthy human volunteers (n=522). COX-1 inhibiting NSAIDs vs. Placebo or no treatment was evaluated on Platelet aggregation (aggregometry) and TxB2 titers.
Synapse has enriched 10 related papers. Consider them for comparative context: